Shares of Repros Therapeutics (NASDAQ: RPRX) dropped 47% in pre-market trade after the reproductive disorders company said its clinical development program for Proellex, its oral delivery mechanism for telapristone acetate, will remain on partial clinical hold, per FDA review and feedback. Repros is now required to compile a large pre-approval safety database to support future development. The company says it is assessing increasing its focus on its uterine fibroid and endometriosis development program utilizing a vaginal drug delivery program for telapristone acetate, and that it expects to receive a European Patent related to the use of selective progesterone modulators (SPRM).
To view the full press release, visit http://nnw.fm/DQ0b0
About Repros Therapeutics Inc.
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. For more information, visit the Company’s website at http://www.reprosrx.com.
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer